US Patent

US10047053 — Deuterated CFTR potentiators

Composition of Matter · Assigned to Vertex Pharmaceuticals Europe Ltd · Expires 2032-05-17 · 6y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects deuterated compounds that act as CFTR potentiators, as well as their pharmaceutically acceptable salts and compositions.

USPTO Abstract

This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

Drugs covered by this patent

Patent Metadata

Patent number: US10047053
Jurisdiction: US
Classification: Composition of Matter
Expires: 2032-05-17
Drug substance claim: Yes
Drug product claim: No
Assignee: Vertex Pharmaceuticals Europe Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.